DWV Stock Overview
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ANGLE plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.15 |
| 52 Week High | UK£0.38 |
| 52 Week Low | UK£0.084 |
| Beta | 0.12 |
| 1 Month Change | 1.35% |
| 3 Month Change | -31.19% |
| 1 Year Change | -32.43% |
| 3 Year Change | -88.28% |
| 5 Year Change | -81.06% |
| Change since IPO | -75.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| DWV | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -2.6% | -5.4% | -2.5% |
| 1Y | -32.4% | -6.2% | -0.4% |
Return vs Industry: DWV underperformed the German Medical Equipment industry which returned -6.2% over the past year.
Return vs Market: DWV underperformed the German Market which returned -0.4% over the past year.
Price Volatility
| DWV volatility | |
|---|---|
| DWV Average Weekly Movement | 19.0% |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: DWV's share price has been volatile over the past 3 months.
Volatility Over Time: DWV's weekly volatility has decreased from 32% to 19% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 173 | Andrew David Newland | angleplc.com |
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer.
ANGLE plc Fundamentals Summary
| DWV fundamental statistics | |
|---|---|
| Market cap | €35.76m |
| Earnings (TTM) | -€26.03m |
| Revenue (TTM) | €2.12m |
16.8x
P/S Ratio-1.4x
P/E RatioIs DWV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DWV income statement (TTM) | |
|---|---|
| Revenue | UK£1.82m |
| Cost of Revenue | UK£1.50m |
| Gross Profit | UK£319.00k |
| Other Expenses | UK£22.60m |
| Earnings | -UK£22.28m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.086 |
| Gross Margin | 17.55% |
| Net Profit Margin | -1,225.41% |
| Debt/Equity Ratio | 0% |
How did DWV perform over the long term?
See historical performance and comparison